32 studies found for:    rigosertib
Show Display Options
Rank Status Study
1 Recruiting Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
Conditions: Myelodysplastic Syndrome;   MDS;   Trisomy 8
Intervention: Drug: rigosertib
Phase: Phase 2
Sponsor: Onconova Therapeutics, Inc.
Study Completion: March 2015
2 Recruiting Oral Rigosertib in Combination With Azacitidine
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Interventions: Drug: oral rigosertib;   Drug: Azacitidine
Phases: Phase 1 / Phase 2
Sponsor: Onconova Therapeutics, Inc.
Study Completion: August 2015
3 Active, not recruiting Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers
Condition: Healthy
Intervention: Drug: rigosertib
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: July 2015
4 Active, not recruiting Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
Condition: Solid Tumor
Intervention: Drug: rigosertib
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: August 2015
5 Active, not recruiting Oral Rigosertib for Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinoma;   Anal Squamous Cell Carcinoma;   Lung Squamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Esophageal Squamous Cell Carcinoma
Intervention: Drug: rigosertib
Phase: Phase 2
Sponsor: Onconova Therapeutics, Inc.
Study Completion: September 2015
6 Active, not recruiting Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: ON 01910.Na
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: February 2015
7 Completed Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer
Conditions: Advanced Cancer;   Solid Tumors;   Cancer;   Neoplasms
Intervention: Drug: rigosertib sodium
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: January 2012
8 Recruiting Three Dosing Schedules of Oral Rigosertib in MDS Patients
Condition: Myelodysplastic Syndrome
Intervention: Drug: rigosertib
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: September 2016
9 Active, not recruiting Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Conditions: Acute Myelocytic Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelocytic Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: ON 01910.Na
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: December 2014
10 Completed Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Conditions: Malignant Neoplasmas;   Solid Tumors
Interventions: Drug: gemcitabine;   Drug: ON 01910.Na
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: September 2011
11 Completed Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer
Conditions: Solid Tumors;   Advanced Cancer;   Cancer;   Neoplasms
Intervention: Drug: rigosertib sodium
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: November 2011
12 Active, not recruiting Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
Conditions: Acute Myelocytic Leukemia;   Acute Lymphocytic Leukemia;   Myeloproliferative Disease;   Chronic Myeloid Leukemia
Intervention: Drug: rigosertib
Phases: Phase 1 / Phase 2
Sponsor: Onconova Therapeutics, Inc.
Study Completion: June 2015
13 Recruiting Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
Condition: Myelodysplastic Syndromes
Intervention: Drug: Oral rigosertib
Phase: Phase 2
Sponsor: Onconova Therapeutics, Inc.
Study Completion: June 2015
14 Completed Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
Condition: Advanced Solid Tumors
Interventions: Drug: ON 01910.Na and irinotecan;   Drug: ON 01910.Na and oxaliplatin
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: July 2011
15 Recruiting Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Conditions: Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Chronic Myelomonocytic Leukemia;   Cytopenia
Intervention: Drug: rigosertib sodium
Phase: Phase 3
Sponsor: Onconova Therapeutics, Inc.
Study Completion: December 2015
16 Recruiting Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
Conditions: Head and Neck Neoplasms;   Carcinoma, Squamous Cell
Interventions: Drug: oral rigosertib;   Drug: cisplatin;   Radiation: Radiotherapy
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: June 2018
17 Active, not recruiting Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: ON 01910.Na;   Drug: Gemcitabine
Phase: Phase 3
Sponsor/Collaborators: Onconova Therapeutics, Inc.;   Academic Oncology Gastrointestinal Cancer Consortium (AGICC)
Study Completion: June 2015
18 Completed Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
Conditions: Hepatoma;   Advanced Solid Tumor
Interventions: Drug: irinotecan and ON 01910.Na;   Drug: oxaliplatin and ON 01910.Na
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: July 2011
19 Completed Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk
Condition: Myelodysplastic Syndrome
Intervention: Drug: ON 01910.Na
Phase: Phase 2
Sponsor: Onconova Therapeutics, Inc.
Study Completion: November 2013
20 Completed
Has Results
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
Condition: Ovarian Cancer
Intervention: Drug: ON 01910.Na
Phase: Phase 2
Sponsor: Onconova Therapeutics, Inc.
Study Completion: July 2011

Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results
Indicates status has not been verified in more than two years